Stem Cell Clinic

Introducing Generate Life Sciences – A First-Of-Its-Kind Company Focused On Helping Grow And Protect Healthy Families – PRNewswire

By Stem Cell Medicine

Generate serves families from preconception to post-birth throughout the significant and highly personalized journey of building a family and protecting their children's health. Built upon the pillars of innovation, access, and connection, Generate has already helped grow and protect nearly 1 million families around the world.

Our legacy brands CBR, California Cryobank, and Donor Egg Bank USA are pioneering leaders in their respective fields and continue to set industry standards for innovation, scientific excellence, and customer focus. Generate is furthering the impact of this life sciences platform with the addition of advanced pediatric genetic testing, US distribution of reproductive medical devices and proprietary healthcare technology through the respective brands ReadyGen (pediatric genetic screening powered by Sema4), Kitazato USA (medical device distribution), and Donor Application (proprietary software for reproductive clinics).

"Our brands are leaders in each of their categories; as a life sciences platform, we are uniquely positioned to give clients access to the full range of expertise and services needed to create and support healthy families," said Richard Jennings, Chief Executive Officer. "Generate helps its clients realize their dreams of having a baby and provides access to scientific innovations in stem cells and genetic services that improve the lives of families around the world."

With the substantial growth in single parenting by choice and LGBTQ+ family building, as well as a trend towards having children later in life, Generate's reproductive health services have never been in higher demand. Similarly, advances in stem cell therapies and research into regenerative medicine have emphasized the importance and increased the awareness and interest in storing newborn stem cells with CBR.

"Generate Life Sciences is positioned to play an increasingly important role in protecting families as regenerative medicine and new genetic testing platforms open the door to the future of personalized medical treatments," said Jaime Shamonki, MD, Chief Medical Officer. "Uniting key elements of the family-building experience under Generate will give our clients peace of mind, convenient access, and exceptional support throughout this significant time in their lives. This organization has collectively helped create nearly 100,000 families and provides access to invaluable long-term health benefits to almost a million more. For us, Generate represents more than just good business; it is advancing scientific innovations that help the future of humanity."

"The journey to parenthood has evolved over the years, but the end goal is the same people want to have children and they want to keep them safe and healthy. In the modern age, we have advanced the science and technology available to help individuals grow their families and be more proactive in planning for their future health," said Michael J. Levy, MD, IVF Director and Co-Founder, Shady Grove Fertility. "That is where Generate Life Sciences becomes a trusted partner for clients from pre-conception through post-birth. From donor egg and donor sperm to newborn stem cell services and genetic testing, Generate is there every step of the way. And the possibilities are endless."

"Generate Life Sciences made our dream of becoming parents a reality. From helping us choose our amazing California Cryobank sperm donor for our twin girls, to rushing a CBR cord blood collection kit for our son when my wife went into early labor, they have always gone above and beyond to help. We look to Generate as a trustworthy partner we can rely on for these very personal and private moments in our lives," said Sharon Kochlany & Vanessa Colimorio, customers of Generate.

Generate Life Sciences BrandsGenerate Life Sciences is a company of established, trustworthy brands founded and grown over 40 years by experts in reproductive medicine, newborn stem cell services, and genetics. Those brands include:

Newborn Stem Cell Services CBR (Cord Blood Registry): CBR has stored newborn stem cells (stem cells collected from cord blood and cord tissue) for almost 30 years.

Reproductive ServicesCalifornia Cryobank Donor Sperm Bank:California Cryobank is a pioneer and industry leader in donor sperm banking, offering the most rigorously screened donors, largest selection, and scientific expertise for more than 40 years.

Donor Egg Bank USA:Donor Egg Bank is a true leader in its category, maintaining the highest clinical pregnancy rate in the industry, while growing the largest frozen donor egg program in the United States.

NW Cryobank:For over 30 years, NW Cryobank has been helping couples, single women, and the LGBTQ+ community create happy, healthy families.

Genetic Services ReadyGen:Powered by Sema4, ReadyGen is an innovative and advanced pediatric screening test that empowers parents to further protect their children by delivering clinically actionable and personalized health insights.

Medical Devices and Healthcare TechnologyKitazato USA:Kitazato USA by California Cryobank is the exclusive distributor of Kitazato products in the US, offering devices for human assisted reproductive medicine from the innovator of the Cryotop Method vitrification technique.

Donor Application: Proprietary software providingdonor screening and recipient matching services on a HIPAA compliant platform.

About Generate Life SciencesGenerate Life Sciences (Generate)is a life sciences company helping to grow and protect families through reproductive, newborn stem cell, genetic screening, medical device, and healthcare technology services. We serve families from preconception to post-birth. Our brands - CBR (Cord Blood Registry), California Cryobank Donor Sperm Bank, Donor Egg Bank USA, NW Cryobank, ReadyGen, Kitazato USA, and Donor Application are pioneering leaders, helping to grow and protect nearly 1 million families. Headquartered in Los Angeles, Generate operates facilities in Tucson, New York, Boston, Palo Alto, and Rockville, MD. Generate is a portfolio company of GI Partners, a private investment firm based in San Francisco.

Media ContactsMonica Rohledermedia@generatelifesciences.com847-606-1973

SOURCE Generate Life Sciences

homepage

See original here:
Introducing Generate Life Sciences - A First-Of-Its-Kind Company Focused On Helping Grow And Protect Healthy Families - PRNewswire

Botox, medical drips and more offered at NVY Center – SILive.com

By Stem Cell Medical Center

STATN ISLAND, N.Y. -- As a Manhattan-based attorney, Chris Cardillo has overseen his share of medical management over the years.

Paperwork involved with being a doctor is so overwhelming these days, he said, noting that many physicians turn to attorneys to help manage their practices.

So with a wide knowledge of the medical industry, he sought to open a business that would house different physicians, as well as spa services, in a medical spa setting under one roof.

The result is NVY Center, a medical management company that opened in Richmond Valley more than one year ago.

As a Manhattan-based attorney, Chris Cardillo has completed his share of medical management over the years. Paperwork involved with being a doctor is so overwhelming these days, he said, noting that many physicians turn to attorneys to help manage their practices. (Staten Island Advance/Tracey Porpora)

I became very interested in the concept because I think its the wave of the future, said Cardillo, who has several partners in the business. Almost every medical office has a medical manager. ...When you go to a hospital, like New York University Medical Center, the hospital does all the management for doctors with affiliated practices. What hospitals do for their doctors, we do on a private level.

MEDICAL, SPA SERVICES UNDER ONE ROOF

NVY Center rents a clean, white expansive space to various medical professionals, and aestheticians, who provide spa services.

We are hoping to be a national brand. What we do is solicit doctors to lease space for us and we manage them. That means when a doctor comes in here the only thing the doctor has to worry about is taking care of the patient, said Cardillo. We take care of the billing. They dont have to do any of the paperwork. Everything they need to do their job is here for them already.

Under the NVY Center roof are an array of spa services -- from stem cell therapy and IV drips to facials and aesthetic injections. (Staten Island Advance/Tracey Porpora)

MEDICAL SPA SERVICES

Under the NVY Center roof are also an array of medical spa services, from stem cell therapy and IV drips, to facials and aesthetic injections.

Included in the facilitys design are individual medical offices, rooms where different procedures, such as facials, can take place, and an IV drip chair area. And the facility always has a medical professional on the premises, said Cardillo.

We do everything from anti-hangover to anti-flu drip. ... Soon, well be able to come to your house and do an IV drip, explained Cardillo. We want this to be a one-stop-shop for modern services."

He noted the IV drips often include vitamins and are used for various purposes, including by those people who desire to lose weight.

We have fast-drips that are 15 minutes long, where we can fill you with fluids if youre not feeling good, said Cardillo. Depending on what were trying to treat, we will mix vitamins and other medicines into the IV drip. But the fluid helps no matter what.

He said the company also hosts IV drip and Botox parties.

Other services include Trusculpting," a fat reduction procedure to lose weight, and laser hair removal, said Cardillo.

NVY CENTER AT A GLANCE

Address: 236 Richmond Valley Rd.

Website: http://www.nvycenter.com

Facebook: http://www.facebook.com/nvycenter/

New Businesses in Focus is a weekly column that relates the stories of new Staten Island businesses owners.

If you have a new business on Staten Island, e-mail porpora@siadvance.com.

MORE NEW BUSINESSES IN FOCUS COLUMNS:

FOLLOW TRACEY PORPORA ON FACEBOOK and TWITTER

Here is the original post:
Botox, medical drips and more offered at NVY Center - SILive.com

Walter named Edward P. Evans Endowed Professor – Washington University School of Medicine in St. Louis

By Stem Cell Medical Center

Visit the News Hub

Oncologist honored for research, patient care in myelodysplastic syndromes

Medical oncologist Matthew Walter, MD, presents his research after being installed as the inaugural Edward P. Evans Endowed Professor of Myelodysplastic Syndromes at Washington University School of Medicine in St. Louis.

Matthew J. Walter, MD, has been named the inaugural Edward P. Evans Endowed Professor of Myelodysplastic Syndromes at Washington University School of Medicine in St. Louis. These syndromes make up a group of rare blood disorders that prevents the body from making sufficient healthy blood cells.

Walter, an international leader in the study and treatment of myelodysplastic syndromes (MDS), is a professor of medicine and director of the Edward P. Evans Center for Myelodysplastic Syndromes at the School of Medicine. The endowed professorship and the center are supported by funding from the Edward P. Evans Foundation, established in 1984 by Edward Parker Evans, a businessman and philanthropist whose foundation supports MDS research nationwide. He died in 2010 from a blood cancer related to MDS.

Walter treats patients with MDS and related blood disorders at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. His new professorship was announced by Chancellor Andrew D. Martin and David H. Perlmutter, MD, executive vice chancellor for medical affairs, the George and Carol Bauer Dean of the School of Medicine, and the Spencer T. and Ann W. Olin Distinguished Professor.

Matthew Walter has devoted his career to the study and treatment of myelodysplastic syndromes, and it is a great pleasure to be able to honor his work and commitment to his patients in this way, Martin said. There is no one better suited to lead this center. This endowed professorship will help support his work to understand the genetic and environmental underpinnings of this disease so that researchers can understand how it develops and work toward developing improved precision therapies to prevent or treat MDS.

Some 40,000 Americans are diagnosed with MDS each year. The symptoms can be vague, including shortness of breath and fatigue, which makes it difficult to diagnose. Low blood cell counts are among the first signs of the disease, and patients are diagnosed based on the appearance of abnormal blood cells. MDS can be fatal, but some patients with low-risk MDS live for many years with the disease and never know they have it. About one-third of patients with MDS develop an aggressive form of the disease that progresses to acute myeloid leukemia (AML), which is a fast-growing blood cancer. Without a successful stem cell transplant, AML is fatal.

Walter is interested in studying patients at risk of developing MDS but who dont yet have the disease. Such patients have mutations in a few important genes linked to MDS but dont yet have symptoms. This condition is called age-related clonal hematopoiesis. Even though relatively few of these patients go on to develop MDS, studying this group of patients could help doctors understand the differences between those who develop MDS and those who dont.

The work that Matthew Walter is leading at the new Edward P. Evans MDS Center, including his work with patients, is the epitome of precision medicine, Perlmutter said. This research will help illuminate what leads patients to progress to MDS or more aggressive blood disorders. His vision includes developing ways to prevent this progression, as well as novel therapies, including immunotherapy strategies. It is a great pleasure to recognize the innovative work Matthew Walter is doing to better care for these patients.

Said Victoria J. Fraser, MD, the Adolphus Busch Professor of Medicine and head of the Department of Medicine: Matthew Walter is a leader in the field in harnessing his labs research discoveries for the benefit of his patients. This professorship will help him continue his important research into the origins of this disease and potential ways to prevent and treat it.

Walter earned his bachelors degree in 1990 from American University in Washington and his medical degree in 1995 from Saint Louis University School of Medicine. He was a research scholar at the Howard Hughes Medical Institute and later completed his internship and residency at Johns Hopkins Hospital. He came to Washington University as a hematology-oncology fellow and joined the faculty in 2004.

Matthew Walter, MD, (center) shakes hands with Washington University Chancellor Andrew D. Martin as Victoria J. Fraser, MD, head of the Department of Medicine, applauds Walters installation as the inaugural Edward P. Evans Endowed Professor of Myelodysplastic Syndromes.

He has been honored with numerous awards, including the Leukemia and Lymphoma Society Scholar Award, the MDS Foundation Young Investigator Award, and the American Society of Hematology Scholar Award. He is an elected member of the American Society for Clinical Investigation, and he serves on the National MDS Steering Committee of the National Institutes of Health (NIH), and on the American Society of Hematology Task Force on Precision Medicine. He is the 2019 chair of the American Society of Hematology Scientific Committee on Myeloid Neoplasia.

Edward Parker Evans ran Spring Hill Farm, the largest thoroughbred breeding farm in Virginia. Since his death, the Edward P. Evans Foundation has supported cutting-edge translational research on MDS at leading institutions across the country, including Washington University, which is noted for its innovative research and leadership in developing new therapies for patients with cancerous disorders of the blood.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

More here:
Walter named Edward P. Evans Endowed Professor - Washington University School of Medicine in St. Louis

Who are the 10 Most Innovative Biopharma Companies? – BioSpace

By Stem Cell Medical Center

As the annual JP Morgan Healthcare Conference draws to a close, lets celebrate the remarkable innovation that drives the biopharma industry. Heres a look at the top 10 companies noted in the BioSpace Ideal Employer 2019 survey for being the most innovative and what theyve been up to recently.

Regeneron Pharmaceuticals. Ranked as the top innovator in the survey, Regeneron has long had a reputation for innovation, and is often cited as Sanofis innovation engine because of its numerous collaborations with the French-based company. Regeneron has seven marketed products, including Arcalyst for rare autoinflammatory disease, Eylea for a common cause of blindness, Praluent for high cholesterol, and Dupixent for atopic dermatitis. It also has REGN-EB3, a three-antibody therapy used to treat Ebola.

On January 9, Regeneron announced results from LUMINA-1, a Phase II trial of garetosmab in patients with fibrodysplasia ossificans progressive (FOP), an ultra-rare genetic disorder that leads to abnormal bone formation. After 28 weeks, the drug decreased total lesion activity compared to placebo by 25%.

Verily Life Sciences. Formerly known as Google Life Sciences, Verily is Alphabets life science research company. It was originally a division of Google X. At this point, the company doesnt have any marketed products and its not completely clear on the companys overall focus. It has numerous partnerships, such as one with Sanofi to develop products for managing diabetes, a disease-detecting nanoparticle platform called project Tricorder, and a partnership with Johnson & Johnson on surgical robotics. It also has partnerships with Alon, 3M, Allergan, Biogen, Dexcon, GlaxoSmithKline, Mayo Clinic, Brigham and Womens Hospital and many others.

On December 23, 2019, Verily partnered with Emory Healthcare to deploy new solutions to help improve cost-effectiveness, operational efficiency and quality. This deal with utilize Emorys academic medical center and partner with Verilys expertise in data science, analytics, user experience and product development. The initial focus is a deep analysis of existing drugs and lab-ordering patterns at Emory.

Illumina. Illumina develops, manufactures, and markets laboratory devices, with particular emphasis on DNA sequencing, genotyping, gene expression and proteomics. On January 4, 2020, Illumina announced a 15-year, non-exclusive deal with Roche. Not only will that increase the availability of next-generation sequencing-based in vitro diagnostic (IVD) tests on Illuminas systems, but the two companies will collaborate to complement Illuminas pan-cancer assay TruSight Oncology 500 (TSO 500) with new companion diagnostic (CDx) claims.

That deal came only a short time after Illumina canceled a $1.2 billion merger with another next-generation sequencing company, Pacific Biosciences (PacBio). Illumina decided the deal was not likely to be approved by antitrust regulators in the U.S. and UK. Illumina holds about 80% of the global DNA sequencing market.

bluebird bio. Bluebird bio focuses on the nascent field of gene therapy. Currently its sole approved product is Zynteglo. It was approved by the European Commission (EC) on June 14, 2019 for patients 12 years or older with transfusion-dependent beta-thalassemia who did not have a 0/0 genotype and for patients where hematopoietic stem cell (HSC) transplantation wasnt appropriate, but a human leukocyte antigen (HLA-matched related HSC donor isnt available. Its a little difficult to mention bluebird without mentioning the price of Zynteglo, which is $1.8 million in Europe. In addition to its scientific innovation, bluebird bio is innovative in terms of pricing structure. Zynteglos price is spread out over five years, with an initial upfront price of 315,000 euros with the four additional yearly payments due only if the treatment continues to work.

The product launched in Germany on Jan. 13, 2020. Bluebird initiated the rolling Biologics Licensing Application for Zynteglo in the U.S. and is currently in discussions with the U.S. Food and Drug Administration (FDA) on the timing and various components of the submission. They hope to complete the BLA submission in the first half of this year.

Biogen. Biogen specializes in therapies for central nervous system disorders. Some of its most well-known products are Alprolix for hemophilia B, Avonex, Fampyra, Tecfidera and Tysabri for multiple sclerosis, and Spinraza for spinal muscular atrophy (SMA). However, most recently, the company has been in the headlines for its aducanumab for Alzheimers disease. The drug was declared a failure in March 2019, but was resurrected this year after some of the later trial data showed effectiveness at the highest dose. Still, its not a slam dunk to be approved by the FDA and there are plenty of skeptics.

Analysts expect Biogen to submit aducanumab to the FDA in a matter of weeks, although the company is being tight-lipped about the timetable.

Bayer. Based in Germany, Bayer is one of the largest pharma companies in the world. In 2018, Bayer acquired U.S.-based Monsanto, which no longer exists under the Monsanto name. The companys business units include Bayer Crop Science, Consumer Health, Pharmaceuticals, Animal Health and Business Services.

On Jan. 16, 2020, Bayer sold one of its last Germany-based manufacturing facilities to Shanghai, China-based WuXi Biologics. The plant will be run by WuXi Biologics and act as a backup site for the manufacture of Bayers Kovaltry (antihemophilic factor). The primary site for Kovaltry product is Bayers facility in Berkeley, California.

Novartis. Based in Switzerland, Novartis has a well-known portfolio of drugs, including Clozaril, Voltaren, Tegretol, Diovan, Gleevec, and Ritalin. Its Sandoz Division is a global leader in generic drugs and biosimilars.

Last year, the FDA approved Zolgensma, a gene therapy for SMA, which was developed by its subsidiary, AveXis. Although there was some controversy over data manipulation in preclinical studies, it was determined not to affect the safety or efficacy of the therapy.

In late November 2019, Novartis acquired The Medicines Company for $9.7 billion, only a week after The Medicines Company announced positive data from its ORION-10 Phase III trial for inclisiran for lowering cholesterol.

GlaxoSmithKline. Headquartered in London, GSK markets drugs for numerous major diseases, such as asthma, cancer, infections, diabetes and mental health. Its best-known drugs include Advair, Augmentin, Flovent, Lamictal and others.

At the recent JP Morgan Healthcare Conference, Emma Walmsley, GSKs chief executive officer, predicted it will have six regulatory approvals in the U.S. this year.

I am pleased with the progress and the momentum that weve been able to make over the past couple years, she told CNBCs Jim Cramer.

Walmsley noted positive data for a number of programs, including ones gained from its $5.1 billion acquisition of Tesaro Oncology in 2018. She also noted a two-drug regimen for HIV that the companys subsidiary ViiV Healthcare has been developing.

Genentech. Generally viewed as the first modern biotechnology company, Genentech is a subsidiary of Swiss-based Roche, although Genentech is based in South San Francisco. It has a laundry list of successful drugs, often in the oncology market, such as Avastin, Tarceva, Zelboraf, Kadcyla, Alecansa, Venclexta and Tecentriq. It also has antivirals, such as Xofluza, Hemlibra for hemophilia A, and Esbriet for idiopathic pulmonary fibrosis.

On Dec. 12, 2019, Genentech announced that its Phase III IMspire150 trial in patients with previously untreated BRAF V600 mutation-positive advanced melanoma, hit its primary endpoint of progression-free survival (PFS). It showed adding Tecentriq to Cotellic and Zeleboraf decreased the risk of the disease getting worse or death, compared to placebo plus Cotellic and Zelboraf.

Amgen. Based in Thousand Oaks, California, Amgens best-selling products are Neulasta, an immunostimulatory for patients undergoing chemotherapy, and Enbrel, used to treat rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Prolia and XGeva.

On Nov. 1, 2019, the company expanded its presence in China by taking a 20.5% stake in China-based BeiGene Co. Amgen paid $2.7 billion in cash for the stake. As a result of the deal, BeiGene will commercialize Xgeva, Kyprolis and Blincyto in China.

On Jan. 13, 2020, the company inked strategic collaborations with Guardant Health and QIAGEN to develop blood- and tissue-based companion diagnostics for investigational cancer treatment AMG 510. AMG 510 is the first KRASG12C inhibitor to advance to the clinic for multiple cancer types.

See the original post here:
Who are the 10 Most Innovative Biopharma Companies? - BioSpace

SVHI PRP Therapy Announces New Website Focused on PRP for Hair Loss in the San Francisco Bay Area – PR Web

By Platelet Rich Plasma Injections

PRP for Hair Loss Bay Area

FOSTER CITY, Calif. (PRWEB) January 17, 2020

SHVI PRP Therapy, the leader in innovative hair loss treatments based on PRP (Platelet Rich Plasma) at https://svhi-prp.com/, is proud to announce a new website. The new website is a "microsite," focused specifically at the use of PRP to mitigate hair loss. Many Bay Area consumers are open to cutting edge technologies, and PRP is one option in their hair loss journey.

"PRP therapy for hair loss is an innovative option for many Bay Area patients," explained Miguel Canales, surgeon and founder of SVHI PRP therapy. "Even more important, a patient who seeks out a consultation with me on hair loss will be able to review the entire range of options from PRP therapy to hair loss to hair transplantation. I will work with each patient to create the best treatment program for their hair loss needs."

Persons who would like to learn more about the company can visit the new website. In particular, they can focus on the page specific to PRP therapy can visit https://svhi-prp.com/prp-therapy/. Another option is to read the FAQ (Frequently Asked Questions) document at https://svhi-prp.com/faq/. That document explains as follows. Hair thinning in women, which affects nearly 40 million American women, is mainly due to heredity and can start any time after puberty. However, we also know that female pattern hair loss can be strongly influenced by age, nutrition, stress, surgery, medications, illness, social/lifestyle factors, hair care and more. As hair follicles weaken and stop producing hair, hair loss occurs. Remarkably, PRP for hair loss can impact the hair itself, often resulting in hair rejuvenation.

PRP or Platelet Rich Plasma for hair loss is an in-office, non-surgical, treatment derived from the patients own blood that can be performed in about an hour. After the area of concern is identified, evaluated and measured, standardized medical photos are taken in the photo suite. Special gentle and sterile techniques and equipment are used to separate and concentrate the platelets and plasma from a small sample of peripheral blood. PRP contains growth factors and cytokines that have been shown to be responsible for stimulating and enhancing hair follicle function. The scalp is prepared with antiseptic solution and anesthetic (a ring block, not simply local anesthetic gel) is used to completely numb the scalp. Small injections of the PRP deliver the powerful platelet-derived growth factors into the skin at the level of the weak follicles. Electronic, mechanical microneedling is performed.

ABOUT SVHI PRP THERAPY

SVHI PRP Therapy is a Bay Area company based in Foster City, California, that offers PRP for hair loss to clients from San Francisco to San Mateo, Palo Alto to Redwood City, Redwood City to Burlingame and beyond. Clients who are suffering from hair loss and are seeking innovative therapy come to SVHI PRP Therapy to explore their options, including PRP therapy for hair loss. The company offers a no obligation consultation on hair loss with Dr. Miguel Canales, a recognized specialist in the hair loss industry including hair transplantation.

Share article on social media or email:

See the original post:
SVHI PRP Therapy Announces New Website Focused on PRP for Hair Loss in the San Francisco Bay Area - PR Web

HEALTH WATCH: What to know about, and how to treat, alopecia – Lexington Dispatch

By Platelet Rich Plasma Injections

Alopecia, or the loss of hair, can be triggered by various causes, including age, stress and an unhealthy lifestyle. [SHUTTERSTOCK]

The loss or thinning of hair can be a very traumatic experience for many, but there are ways to treat it

If one's hair begins to significantly thin out or fall out, it can be quite distressing for many. Alopecia, or hair loss, is a common condition that impacts men, women and even children.

Dr. Rosalyn George, a dermatologist and the founder of Wilmington Dermatology Center, 710 Military Cutoff Road, Suite 320, said alopecia is a daily complaint in her office and is a huge problem for many. She recommends that anyone who experiences significant hair loss get evaluated by a board-certified dermatologist.

1) Alopecia can appear as one or more circular bald patches, shedding of hair and gradual hair loss

"Alopecia is the technical term for hair loss, and it can present in many different ways depending on what's causing it," George said. "There are some autoimmune diseases where it will show up as a circular patch where all of your hair is gone. Most commonly people will notice a thinning or shedding of their hair, so they'll notice their hair is not quite as thick or that they're losing a lot more of their hair."

2) Alopecia types can be placed into two categories -- scarring alopecia and non-scarring alopecia

According to the National Institute or Arthritis and Musculoskeletal and Skin Diseases, scarring alopecia, also called cicatricial alopecia, is a group of rare disorders that destroy hair follicles, the part of the skin from which hair grows. Scar tissue replaces the follicles, causing permanent hair loss.

"It's very important to get that diagnosed early cause we (can) treat them before people have permanent hair loss," George said. "And then there are the non-scarring alopecias, which are the vast majority of alopecia that we see ...

"If someone's noticing significant hair loss, or if someone is having symptoms -- like some of the scarring hair loss will be itchy or have redness around the hair follicles, so there may be other things going on with that type of hair loss, so it's important to have a dermatologist evaluate you."

3) Telogen effluvium, androgenetic alopecia and alopecia areata are common types of alopecia

Non-scarring alopecia is the most common type of alopecia and include telogen effluvium, androgenetic alopecia and alopecia areata.

"The telogen effluvium happens in times of stress -- a good stress or a bad stress," George said. "For example, during pregnancy you kind of keep all of your hair, and then once you have the baby all of that hair will shed. That can happen after someone has surgery; I see it after someone has gastric bypass surgery, where their nutrition isn't great ..."

George calls androgenetic alopecia "extraordinarily widespread." It includes hair loss caused by aging. "That's the type of hair loss that men notice when they're starting to get the widow's peak, or they are going bald on the crown of their heads. It's very terrible for women when this happens because their hair starts to thin, and it can be very distressing psychologically to people.

"The third one is alopecia areata -- that's where people lose very well demarcated areas of hair or they can lose all of their hair on their scalp, or their body. There's different variations," she said. "Most of the times it's very localized, but there are more severe cases, where people can lose all of their hair on their body or just all of the hair on their head and face."

4) Alopecia can have various causes

According to the National Library of Medicine, many men and some women lose their hair as they get older. Hair loss can also be caused by underlying diseases, such as thyroid problems, diabetes, or lupus. Certain medications, types of chemotherapy, a stressful experience, diet, family history, and poor nutrition are some other causes.

"It's a mixture of genes, hormone changes, and environmental influences that cause hair loss over time and that is very, very common," George said about androgenetic alopecia.

Alopecia areata is an autoimmune condition, in which one's immune system basically attacks the hair follicles, which causes hair loss.

5) Treatment for alopecia depends on the cause

In some cases, treating the underlying cause can correct the problem. Other forms of treatment include medication and hair restoration techniques. One treatment for androgenetic alopecia includes Minoxidil, also known by brand name Rogaine. George said some vitamins can be helpful and some hair supplements have been linked to helping hair growth. However, she cautioned use of biotin, as excessive use of it can affect important lab work. A new therapy being used for hair loss is platelet-rich plasma injections, or PRP, where a person's blood is drawn, processed, and then injected into the scalp to help stimulate new hair growth.

George said, reducing stress, having a good diet, and getting enough sleep can all be helpful. Though trials are underway for oral medicines for people with alopecia areata, currently there are no approved medications for it.

As for telogen effluvium, George said, "all that takes is time. The hair recovers, and it grows back. It's not anything permanent, but it can be very stressful for people because you're shedding a lot of hair."

Contact the newsroom at 910-343-2384 or Breakingnews@StarNewsOnline.com.

Go here to read the rest:
HEALTH WATCH: What to know about, and how to treat, alopecia - Lexington Dispatch

Heart Cell Research Leads to Discovery That May Lead to Unreliable Data – Newswise

By Stell Cell Research

MEDIA CONTACT

Available for logged-in reporters only

American Journal of PhysiologyCell Physiology

Research Results

MEDICINE

Newswise Rockville, Md. (January 16, 2020)Researchers studying proteins in heart cells have unexpectedly discovered that a common microscopy fluorescent protein carries reversible photobleaching properties. This phenomenon may lead to inaccurate or unreliable data. The study is published ahead of print in the American Journal of PhysiologyCell Physiology and was chosen as an APSselect article for January.

Fluorescence recovery after photobleaching (FRAP) is a technique that uses fluorescent microscopy to determine the amount and rate of protein movement in a cell or region of a cell. Scientists using FRAP mark a part of a cell with a fluorescent protein tag and take time-lapse images to capture the cells fluorescent protein signal. Then, they use a high-power laser that removes the proteins fluorescence in a process called photobleaching. The final phase of FRAP is recovery: the cell begins to emit fluorescence again when new fluorescent proteins are produced or transported within the cell.

One important principle in FRAP is the assumption that photobleaching is irreversible, as the [laser] disrupts the fluorescence protein structure and function, explains Adrian Cadar, PhD, first author of the study.

Researchers performed FRAPusing a fluorescent protein called mEos3.2on beating human heart cells to learn more about the turnover of titin. Titin is a very large, elastic protein that forms a complex molecular framework of muscle cells called the sarcomere. Previous research has found that the sarcomere is a dynamic structure in which there is a constant and rapid exchange of titin molecules. However, in the current study, titin tagged with mEos3.2 had a much quicker recovery time than the research team had anticipated. To determine if the recovery signal was indeed due to titin movement, the team performed a critical control by treating the cells with paraformaldehydea process called fixation. The fixation process crosslinks the proteins within the cell together, thus immobilizing them. The researchers then performed FRAP in these fixed cells, which surprisingly revealed a fluorescence recovery signal similar to the initial live cell measurements. The researchers discovered that, unlike other proteins used in FRAP, mEos3.2 refolds or restructures itself to regain fluorescence. This reversibility leads to unreliable data.

When using fluorescent proteins for FRAP studies, it is important that one validates the photo-properties of their particular fluorescent protein. In our case, the mEos3.2 photoconvertible fluorescent protein displayed a significant reversible photobleaching property which hasnt been described before. This property makes the mEos3.2 fluorescent protein an inappropriate tool for FRAP studies as the reversible photobleaching led to an overestimation of the fluorescent recovery signal, Cadar wrote.

Read the full article, Real-time visualization of titin dynamics reveals extensive reversible photobleaching in human induced pluripotent stem cell-derived cardiomyocytes, published ahead of print in the American Journal of PhysiologyCell Physiology. It is highlighted as one of this months best of the best as part of the American Physiological Societys APSselect program. Read all of this months selected research articles.

NOTE TO JOURNALISTS:To schedule an interview with a member of the research team, please contact theAPS Communications Officeor call 301.634.7314. Find more research highlights in our News Room.

Physiology is the study of how molecules, cells, tissues and organs function in healthand disease.Established in 1887, the American Physiological Society (APS) was the first U.S. society in the biomedical sciences field. The Society represents nearly 10,000 members and publishes 15 peer-reviewed journals with a worldwide readership.

Original post:
Heart Cell Research Leads to Discovery That May Lead to Unreliable Data - Newswise

Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market 2019 Valuable Growth Prospects and Upcoming Trends till 2024 Dagoretti News…

By Stell Cell Research

Industry Research Report On GlobalStem Cell and Platelet Rich Plasma (PRP) Alopecia TherapiesMarket Quantitative And Qualitative Analysis

GlobalStem Cell and Platelet Rich Plasma (PRP) Alopecia TherapiesMarketis a new market res earch study recently announced byMRInsights.biz. The report studies theStem Cell and Platelet Rich Plasma (PRP) Alopecia Therapiesindustrys coverage, current market competitive status, and market outlook and forecast by 2024. The report clarifies business verticals like aggressive market situation, regional nearness, and improvement openings. The report is incomplete without having the knowledge of the key players or competitors within the market. Different sidelines of the area along with a SWOT investigation of the real players have been demonstrated in the report.

The report serves an overall market overview onStem Cell and Platelet Rich Plasma (PRP) Alopecia Therapiesmarket dynamics, historic volume and value, current & future trends, market methodology, Porters Five Forces Analysis, upstream and downstream industry chain, and cost structure. Further, the report has analyzed sales, suppliers, nations, advance technology, production, the variable cost, types, sales, and market share for the approximate time from 2019 to 2024. The report accounts for various market factors including development, confinements, and the organized attributes of a component of the market. The report investigates the type of product, its applications, customers, prime players, and various components related to the market. The report examines the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges.

DOWNLOAD FREE SAMPLE REPORT:https://www.mrinsights.biz/report-detail/220643/request-sample

Company Profile:

The report presents theStem Cell and Platelet Rich Plasma (PRP) Alopecia Therapiescompany profile, descriptions of the product, and production values along with the assistance of the statistical review. The report reveals the all-inclusive global market covering magnitude, production, manufacturing value, loss/gain, supply/demand, and import/export. Many companies are operating in the market and conduct their businesses through joint ventures, which benefit the overall market. The key players analysis for the industry is presented in this report.

Crucial leading players of industry:Orange County Hair Restoration Center, Colorado Surgical Center & Hair Institute, Evolution Hair Loss Institute, Hair Sciences Center of Colorado, Hair Transplant Institute of Miami, Anderson Center for Hair, Virginia Surgical Center, Savola Aesthetic Dermatology Center,

The global version of this report with a geographical classification such as:

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

The next part of the report offers markets vital information and statistically evaluated technical data and manufacturing plants analysis with regards to capacity analysis, sales analysis, and sales price analysis. It mainly scrutinizes in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it. By identifying the growth, size, leading players and segments in the globalStem Cell and Platelet Rich Plasma (PRP) Alopecia Therapiesmarket, the report will save and reduce the time taken by entry-level research. The research has used immense data sources and various tools and techniques to collect and analyze the information.

Main Pointers Presented In TheStem Cell and Platelet Rich Plasma (PRP) Alopecia TherapiesMarket Report:

ACCESS FULL REPORT:https://www.mrinsights.biz/report/global-stem-cell-and-platelet-rich-plasma-prp-220643.html

Moreover, the report comprises predictions using a proper set of assumptions and methodologies. For predictions on market values, the researchers have used several methodological, analytical, and statistical techniques, such as probability, standard deviation, and CAGR. Additionally, the report research report estimatesStem Cell and Platelet Rich Plasma (PRP) Alopecia Therapiesmarket necessary characteristics, including profit, potential application rate, cost, development ratio, level of investments, production, and provision.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Read more here:
Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market 2019 Valuable Growth Prospects and Upcoming Trends till 2024 Dagoretti News...

In Vitro Lung Model Market to 2027 Increasing Adoption Of 3D Model Systems – PharmiWeb.com

By Stell Cell Research

Opportunity & Market Drivers: Significant Growth in Research Funding, Rising Research on Lung Diseases, Increasing Number of Start-Up Companies

The global in vitro lung model market is expected to reach US$ 701.81 Mn in 2027 from US$ 185.80 Mn in 2018. The market is estimated to grow with a CAGR of 16.2% from 2019-2027.

Get PDF Sample Brochure at https://decisionmarketreports.com/request-sample/1263397

Driving factors of the in vitro lung model are significant growth in research funding, and increasing adoption of 3d model systems for in vitro studies. Also, growing research on lung diseases is likely to have a positive impact on the growth of the market in the coming years. Besides, rising healthcare expenditure, and advancements in cell culture techniques is likely to have a positive effect on the growth of the market in the forecast years.

The cases of asthma, lung cancer, and COPD has been growing across the globe at a significant rate. Thus there is a growing need to study lung diseases specifically. Since early 2010s the practices of creating lab-grown organ buds, mostly referred to as organoids, have become more popular. These organ buds are miniature organ-like structures that are maintained in the lab, and researchers are able to grow these organoids, which resembles human body tissues. Lung diseases, like idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD), is a significant cause of death and illness worldwide. A recently published report by Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California developed a new system for building lung 3D organoids to model lung disease. Moreover, Lung cancer cell lines have made a significant contribution to lung cancer research and biomedical discovery. The high similarities between lung cancer cell lines and the lung tumor helps in discovering new drug molecules. Thus the growing research on lung diseases is expected to offer broad growth opportunities for the in vitro lung model market at the global level.

Know More about discounts & methodology: https://decisionmarketreports.com/request-methodolgy/1263397

The global in vitro lung model market is segmented by type, and application. On the basis of type, the market is segmented into 2D and 3D. The 3D segment is expected to dominate the type segment market as 3D cell culture gives better phenotypes insights which are poorly reproduced in conventional 2D cell culture, Based on the application, market is segmented into drug screening, toxicology, 3d model development, physiologic research, stem cell research, and regenerative medicine. Toxicology segment is expected to dominate the application segment during the forecast period.

Some of the important primary and secondary sources included in the report are, Food and Drug Administration, World Health Organization (WHO), American Society of Clinical Oncology, American Type Culture Collection, Centers for Disease Control and Prevention, Canadian Lung Association and others.

About Us

Decision Market Reports is a one-stop solution, covers market research studies of all the industries, companies and regions. DMR aims at providing quality research, and insights about every market to helps our clients in taking right decisions. Our repository consists of most trending industry reports, niche areas, and leading company profiles. A comprehensive collection of reports is updated daily to offer hassle-free access to our latest updated report databases.

Contact Us

Gasper James

304, S Jones Blvd,

Las Vegas,

NV 89107, USA

US Toll Free +18666051052

Email: sales@decisionmarketreports.com

Web: http://decisionmarketreports.com/

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at contact@wiredrelease.com.

Continued here:
In Vitro Lung Model Market to 2027 Increasing Adoption Of 3D Model Systems - PharmiWeb.com

Stem Cell Assay Market Predicted to Accelerate the Growth by 2017-2025 Dagoretti News – Dagoretti News

By Embryonic Stem Cells

Stem Cell Assay Market: Snapshot

Stem cell assay refers to the procedure of measuring the potency of antineoplastic drugs, on the basis of their capability of retarding the growth of human tumor cells. The assay consists of qualitative or quantitative analysis or testing of affected tissues and tumors, wherein their toxicity, impurity, and other aspects are studied.

Download Brochure of This Market Report at https://www.tmrresearch.com/sample/sample?flag=B&rep_id=40

With the growing number of successful stem cell therapy treatment cases, the global market for stem cell assays will gain substantial momentum. A number of research and development projects are lending a hand to the growth of the market. For instance, the University of Washingtons Institute for Stem Cell and Regenerative Medicine (ISCRM) has attempted to manipulate stem cells to heal eye, kidney, and heart injuries. A number of diseases such as Alzheimers, spinal cord injury, Parkinsons, diabetes, stroke, retinal disease, cancer, rheumatoid arthritis, and neurological diseases can be successfully treated via stem cell therapy. Therefore, stem cell assays will exhibit growing demand.

Another key development in the stem cell assay market is the development of innovative stem cell therapies. In April 2017, for instance, the first participant in an innovative clinical trial at the University of Wisconsin School of Medicine and Public Health was successfully treated with stem cell therapy. CardiAMP, the investigational therapy, has been designed to direct a large dose of the patients own bone-marrow cells to the point of cardiac injury, stimulating the natural healing response of the body.

Newer areas of application in medicine are being explored constantly. Consequently, stem cell assays are likely to play a key role in the formulation of treatments of a number of diseases.

Global Stem Cell Assay Market: Overview

The increasing investment in research and development of novel therapeutics owing to the rising incidence of chronic diseases has led to immense growth in the global stem cell assay market. In the next couple of years, the market is expected to spawn into a multi-billion dollar industry as healthcare sector and governments around the world increase their research spending.

The report analyzes the prevalent opportunities for the markets growth and those that companies should capitalize in the near future to strengthen their position in the market. It presents insights into the growth drivers and lists down the major restraints. Additionally, the report gauges the effect of Porters five forces on the overall stem cell assay market.

Global Stem Cell Assay Market: Key Market Segments

For the purpose of the study, the report segments the global stem cell assay market based on various parameters. For instance, in terms of assay type, the market can be segmented into isolation and purification, viability, cell identification, differentiation, proliferation, apoptosis, and function. By kit, the market can be bifurcated into human embryonic stem cell kits and adult stem cell kits. Based on instruments, flow cytometer, cell imaging systems, automated cell counter, and micro electrode arrays could be the key market segments.

In terms of application, the market can be segmented into drug discovery and development, clinical research, and regenerative medicine and therapy. The growth witnessed across the aforementioned application segments will be influenced by the increasing incidence of chronic ailments which will translate into the rising demand for regenerative medicines. Finally, based on end users, research institutes and industry research constitute the key market segments.

The report includes a detailed assessment of the various factors influencing the markets expansion across its key segments. The ones holding the most lucrative prospects are analyzed, and the factors restraining its trajectory across key segments are also discussed at length.

Global Stem Cell Assay Market: Regional Analysis

Regionally, the market is expected to witness heightened demand in the developed countries across Europe and North America. The increasing incidence of chronic ailments and the subsequently expanding patient population are the chief drivers of the stem cell assay market in North America. Besides this, the market is also expected to witness lucrative opportunities in Asia Pacific and Rest of the World.

Global Stem Cell Assay Market: Vendor Landscape

A major inclusion in the report is the detailed assessment of the markets vendor landscape. For the purpose of the study the report therefore profiles some of the leading players having influence on the overall market dynamics. It also conducts SWOT analysis to study the strengths and weaknesses of the companies profiled and identify threats and opportunities that these enterprises are forecast to witness over the course of the reports forecast period.

Some of the most prominent enterprises operating in the global stem cell assay market are Bio-Rad Laboratories, Inc (U.S.), Thermo Fisher Scientific Inc. (U.S.), GE Healthcare (U.K.), Hemogenix Inc. (U.S.), Promega Corporation (U.S.), Bio-Techne Corporation (U.S.), Merck KGaA (Germany), STEMCELL Technologies Inc. (CA), Cell Biolabs, Inc. (U.S.), and Cellular Dynamics International, Inc. (U.S.).

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=40

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

View original post here:
Stem Cell Assay Market Predicted to Accelerate the Growth by 2017-2025 Dagoretti News - Dagoretti News

→←